Samsung Biologics has announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland, from GSK.
The move means the company has established its first manufacturing presence in the US.
The Rockville site comprises two cGMP manufacturing plants with a combined 60,000-litre capacity for drug substance, supporting both clinical and commercial biologics production across multiple manufacturing scales.
With the addition of the site, Samsung Biologics' total global manufacturing capacity has now increased to 845,000 litres.
The CDMO will continue supplying the products previously manufactured at the site to GSK under the terms of the agreement and the site will transition to serve additional contract manufacturing needs.
The company has also stated it plans further investments to expand the site's capacity and upgrade technologies, reinforcing its long-term commitment to advancing a more resilient global supply chain and improving patient access to critical medicines.
"This represents a meaningful step in expanding our US manufacturing footprint," said John Rim, President and CEO of Samsung Biologics.
"The addition of the Rockville site strengthens our ability to operate a geographically diversified manufacturing network and we are thrilled to officially welcome more than 500 colleagues at the site to the Samsung Biologics family."
"The Rockville team brings deep expertise and strong operational experience that will further strengthen the site as part of our global manufacturing network."
As a CDMO, our mission is to help our partners bring important therapies to patients worldwide and this site will play a pivotal role in that mission while ensuring continuity and upholding the high standards our clients expect.
The completion follows the previously announced agreement to acquire the facility, which was announced on December 22, 2025.